Presidential Symposium 2 A Fascinating Era for Myeloproliferative Neoplasms

[PSY2-4] Interferon alpha (IFNa) renaissance in myeloproliferative neoplasms (MPN)

Jean-Jacques Kiladjian^1,2,3 (1.Clinical Investigations Center, Saint-Louis Hospital, France, 2.Universite de Paris, France, 3.INSERM, France)

Jean-Jacques Kiladjian is Professor of Clinical Pharmacology at Universit de Paris, consultant Hematologist, and head of the Clinical Investigation Centre of the Saint-Louis Hospital, Paris, France.Pr. Kiladjian’s research has centered on Myeloproliferative neoplasms and Myelodysplastic syndromes, evaluating novel therapeutics and implementing clinical trials. He is published in many peer-reviewed journals including The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, etc., and has authored several book chapters. He is an active member of many societies including the European Hematology Association (EHA) (chair of the Scientific Working Group on Myeloproliferative Neoplasms), the American Society of Hematology (ASH), the European LeukemiaNet (ELN, Secretary of the working group on myeloproliferative neoplasms), the European School of Hematology (ESH, scientific committee). Pr. Kiladjian was elected President of the French Intergroup of Myeloproliferative disorders (FIM group) since 2008.